NCT/Study#
NA /
PTX-001-004
A Phase 2 Study Of The Safety and Tolerability of Sargramostim Added To Standard Of Care Ipilimumab Containing Checkpoint Inhibitor Therapy In Patients With Solid Tumors
DISEASE GROUP:
Solid Tumors
current phase:
II
STUDY STATUS:
Active
Location:
For More information:
Call 201-518-3587
